Annual CFF:
$304.12M+$163.99M(+117.02%)Summary
- As of today, RXRX annual cash from financing is $304.12 million, with the most recent change of +$163.99 million (+117.02%) on December 31, 2024.
- During the last 3 years, RXRX annual cash from financing has fallen by -$154.42 million (-33.68%).
- RXRX annual cash from financing is now -33.68% below its all-time high of $458.54 million, reached on December 31, 2021.
Performance
RXRX Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly CFF:
$97.66M+$57.13M(+140.97%)Summary
- As of today, RXRX quarterly cash from financing is $97.66 million, with the most recent change of +$57.13 million (+140.97%) on June 30, 2025.
- Over the past year, RXRX quarterly cash from financing has dropped by -$165.46 million (-62.88%).
- RXRX quarterly cash from financing is now -78.94% below its all-time high of $463.70 million, reached on June 30, 2021.
Performance
RXRX Quarterly Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM CFF:
$165.29M-$165.46M(-50.03%)Summary
- As of today, RXRX TTM cash from financing is $165.29 million, with the most recent change of -$165.46 million (-50.03%) on June 30, 2025.
- Over the past year, RXRX TTM cash from financing has dropped by -$246.16 million (-59.83%).
- RXRX TTM cash from financing is now -76.57% below its all-time high of $705.60 million, reached on June 30, 2021.
Performance
RXRX TTM Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
RXRX Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1Y1 Year | +117.0% | -62.9% | -59.8% |
| 3Y3 Years | -33.7% | +3560.4% | +6589.5% |
| 5Y5 Years | +152.6% | +10000.0% | -30.0% |
RXRX Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | TTM vs HighTTM vs High | TTM vs LowTTM vs Low | |
|---|---|---|---|---|---|---|---|
| 3Y | 3-Year | -33.7% | +117.0% | -62.9% | +4981.1% | -59.8% | +1418.5% |
| 5Y | 5-Year | -33.7% | +152.6% | -78.9% | +980.2% | -76.6% | +6589.5% |
| All-Time | All-Time | -33.7% | +152.6% | -78.9% | +980.2% | -76.6% | +6589.5% |
RXRX Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | $97.66M(+141.0%) | $165.29M(-50.0%) |
| Mar 2025 | - | $40.53M(+280.9%) | $330.75M(+8.8%) |
| Dec 2024 | $304.12M(+117.0%) | $10.64M(-35.4%) | $304.12M(-18.7%) |
| Sep 2024 | - | $16.46M(-93.7%) | $374.14M(-9.1%) |
| Jun 2024 | - | $263.12M(+1793.4%) | $411.44M(+170.5%) |
| Mar 2024 | - | $13.90M(-82.8%) | $152.11M(+8.5%) |
| Dec 2023 | $140.13M(-9.2%) | $80.66M(+50.0%) | $140.13M(-32.2%) |
| Sep 2023 | - | $53.77M(+1319.7%) | $206.73M(+33.1%) |
| Jun 2023 | - | $3.79M(+97.0%) | $155.30M(+0.7%) |
| Mar 2023 | - | $1.92M(-98.7%) | $154.18M(-0.1%) |
| Dec 2022 | $154.34M | $147.26M(+6201.1%) | $154.34M(+1318.0%) |
| Sep 2022 | - | $2.34M(-12.4%) | $10.88M(+527.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2022 | - | $2.67M(+28.0%) | -$2.55M(-100.6%) |
| Mar 2022 | - | $2.08M(-45.1%) | $458.49M(-0.0%) |
| Dec 2021 | $458.54M(+86.3%) | $3.80M(+134.2%) | $458.54M(-1.3%) |
| Sep 2021 | - | -$11.10M(-102.4%) | $464.78M(-34.1%) |
| Jun 2021 | - | $463.70M(>+9900.0%) | $705.60M(+191.2%) |
| Mar 2021 | - | $2.13M(-78.7%) | $242.27M(-1.6%) |
| Dec 2020 | $246.13M(+104.4%) | - | - |
| Dec 2020 | - | $10.04M(-95.6%) | $246.13M(+4.3%) |
| Sep 2020 | - | $229.72M(>+9900.0%) | $236.10M(+3601.2%) |
| Jun 2020 | - | $382.00K(-93.6%) | $6.38M(+6.4%) |
| Mar 2020 | - | $6.00M | $6.00M |
| Dec 2019 | $120.41M | - | - |
FAQ
- What is Recursion Pharmaceuticals, Inc. annual cash from financing?
- What is the all-time high annual cash from financing for Recursion Pharmaceuticals, Inc.?
- What is Recursion Pharmaceuticals, Inc. annual cash from financing year-on-year change?
- What is Recursion Pharmaceuticals, Inc. quarterly cash from financing?
- What is the all-time high quarterly cash from financing for Recursion Pharmaceuticals, Inc.?
- What is Recursion Pharmaceuticals, Inc. quarterly cash from financing year-on-year change?
- What is Recursion Pharmaceuticals, Inc. TTM cash from financing?
- What is the all-time high TTM cash from financing for Recursion Pharmaceuticals, Inc.?
- What is Recursion Pharmaceuticals, Inc. TTM cash from financing year-on-year change?
What is Recursion Pharmaceuticals, Inc. annual cash from financing?
The current annual cash from financing of RXRX is $304.12M
What is the all-time high annual cash from financing for Recursion Pharmaceuticals, Inc.?
Recursion Pharmaceuticals, Inc. all-time high annual cash from financing is $458.54M
What is Recursion Pharmaceuticals, Inc. annual cash from financing year-on-year change?
Over the past year, RXRX annual cash from financing has changed by +$163.99M (+117.02%)
What is Recursion Pharmaceuticals, Inc. quarterly cash from financing?
The current quarterly cash from financing of RXRX is $97.66M
What is the all-time high quarterly cash from financing for Recursion Pharmaceuticals, Inc.?
Recursion Pharmaceuticals, Inc. all-time high quarterly cash from financing is $463.70M
What is Recursion Pharmaceuticals, Inc. quarterly cash from financing year-on-year change?
Over the past year, RXRX quarterly cash from financing has changed by -$165.46M (-62.88%)
What is Recursion Pharmaceuticals, Inc. TTM cash from financing?
The current TTM cash from financing of RXRX is $165.29M
What is the all-time high TTM cash from financing for Recursion Pharmaceuticals, Inc.?
Recursion Pharmaceuticals, Inc. all-time high TTM cash from financing is $705.60M
What is Recursion Pharmaceuticals, Inc. TTM cash from financing year-on-year change?
Over the past year, RXRX TTM cash from financing has changed by -$246.16M (-59.83%)